

17 South High Street, Suite 400 • Columbus, Ohio 43215-7410 • (614) 466-3947

New Drugs List- 5/2/2016 to 9/13/ 2016) Review on October 17, 2016

(Original New Drug Applications: FDA)

| Generic Name | Trade Name | Indication(s) | CPG Action/Date |
|------------------|--------------|---|---|
| cabozantinib s- | Cabometyx | Antineoplastic Agents: | Current Category |
| malate | Cabolifictyx | Kinase Inhibitors; | Prescribing |
| maiate | | Tyrosine Kinase | Parameters: May |
| | | Inhibitors | not prescribe |
| | | Treatment of | not presente |
| | | advanced renal cell | |
| | | carcinoma. | |
| pimavanserin | Nuplazid | Central Nervous | Current Category |
| piillavariscriii | ΙναριαΖία | System Agents: | Prescribing |
| | | Antipsychotic Agents; | Parameters: In |
| | | Second Generation | accordance |
| | | (Atypical) | (same type as |
| | | Treatment of | Clozapine) |
| | | hallucinations and | σιοΣαριτίο |
| | | delusions associated | |
| | | with Parkinson | |
| | | disease psychosis. | |
| atezolizumab | Tecentriq | Antineoplastic Agents: | Current Category |
| atczonzamab | recenting | Monoclonal | Prescribing |
| | | Antibodies | Parameters: May |
| | | (Antineoplastic) | not prescribe |
| | | Treatment of locally | not presente |
| | | advanced or | |
| | | metastatic urothelial | |
| | | carcinoma in patients | |
| | | who have disease | |
| | | progression during or | |
| | | following platinum- | |
| | | containing | |
| | | _ | |
| obeticholic | Ocaliva | • | Current Category |
| Obelicione | Joanva | | • |
| | | • | _ |
| | | , , | |
| | | | |
| | | | |
| | | | |
| | | inadequate response | |
| | | to UDCA, or as a | |
| obeticholic | Ocaliva | chemotherapy Gastrointestinal Agents: Farnesoid X Receptor Agonists: Oral tablets for the treatment of primary biliary cholangitis with UDCA in adults with | Current Category Prescribing Parameters: (new subcategory) |

| linagliptin/metformin HCL | Jentadueto XR (new formulation of existing drug) | monotherapy in adults unable to tolerate UDCA. Endocrine and Metabolic Agents: Antidiabetic Agents; Antidiabetic Combination Products. New formulation of existing drug in combination. Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes for the treatment of type 2 diabetes in adults. | Current Category Prescribing Parameters: May prescribe |
|------------------------------|--|--|---|
| daclizumab | Zinbryta | Biologic and Immunological Agents: Immunologic Agents; Immunomodulators Once monthly, subcutaneous injection for the treatment of adults with relapsing forms of multiple sclerosis. Should generally be reserved for patients who have had an inadequate response to 2 or more MS drugs. | Current Category Prescribing Parameters: In accordance with SCA (Keytruda is may not prescribe) |
| Nebivolol/Valsartan | Byvalson | Cardiovascular Agents: Antihypertensive Combinations | Current Category Prescribing Parameters: May prescribe |
| cholera vaccine | Vaxchora | Biologic and Immunological Agents: Agents for Active Immunization: Vaccines, Bacterial: Provides active immunization against | Current Category Prescribing Parameters: May prescribe |

| | | disease caused by Vibrio cholera serogroup O1 in adults 18 through 64 years of age traveling to cholera-affected areas. | |
|--|----------|---|---|
| calcifediol | Rayaldee | Therapeutic Categories: Nutrients and Nutritional agents: Vitamins; Fat- Soluble Vitamins For secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and serum total 25- hydroxyvitamin D levels less than 30ng/ml | Current Category Prescribing Parameters: May prescribe |
| sofosbuvir 400mg and velpatasvir 100mg | Epclusa | Anti-Infective Agents: Antiviral Agents; Hepatitis C Virus Direct-Acting Antivirals Treatment of genotype chronic Hepatitics C (CHC) 1, 2, 3, 4, 5, or 6 infection in adult patients without cirrhosis or with compensated cirrhosis or in combination with ribavirin in patients with decompensated cirrhosis. | Current Category Prescribing Parameters: In accordance with the SCA |
| lifitegrast | Xiidra | Ophalmic and Otic Agents: Ophalmic Lymphocyte Function- Associated Antigen-1 Antagonists Treatment of the signs and symptoms of dry eye disease. | Current Category Prescribing Parameter: (new subcategory) |

| lixisenatide | Adlyxin | Endocrine and Metabolic Agents: Antidiabetic Agents; Glucagonlike Peptide 1 Receptor Agonists Treatment of type 2 diabetes mellitus to improve glycemic control in adult patients as an adjunct to diet and exercise. | Current Category Prescribing Parameter: May prescribe |
|--|---|---|--|
| | SMOFlipid (awaiting full monograph) | ******** | ****** |
| Granisetron extended release injection | Sustol (awaiting revised monograph) | Central Nervous System Agents: Antiemtic/Antivertigo Agents; 5-HT3 Receptor Antagonists Prevention of chemotherapy- induced nausea and vomiting. | Current Category Prescribing Parameters: In accordance with SCA (see Emend) |
| Oxycodone/ naltrexone | Troxyca ER | Central Nervous System Agent: Opioid Agonist-Antagonist Analgesics Management of pain severe enough to require daily, around- the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. | Current Category Prescribing Parameters: (same drug subcategory as Suboxone). |
| Afluria Quadrivalent | Influenza vaccine, inactivated | Biologic and Immunlogical Agents; Agents for active immunization; Vaccines Vital; Influenza types A and B Vaccine. Active immunization for adults against influenza disease caused by influenza | Current Category Prescibing Parameters: May prescribe |

| | A subtype viruses and type B viruses contained in the vaccine. |
|--|--|
|--|--|